Boehringer Ingelheim, Lilly (LLY) Report Encouraging Data for Empagliflozin as Add-On to Metformin in Reducing A1C Levels in Type 2 Diabetes Patients
Tweet Send to a Friend
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) presented results that showed empagliflozin (BI 10773), alone or ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
